277 related articles for article (PubMed ID: 32910549)
1. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1).
Arcelli A; Tarantino G; Cellini F; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Ma J; Strigari L; Mazzarotto R; Morganti AG
Curr Oncol; 2023 Jun; 30(6):5690-5703. PubMed ID: 37366910
[TBL] [Abstract][Full Text] [Related]
3. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
4. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1).
Arcelli A; Guido A; Buwenge M; Simoni N; Mazzarotto R; Macchia G; Deodato F; Cilla S; Bonomo P; Scotti V; Belgioia L; Tolento G; Cellini F; Grassi E; DI Marco M; Casadei R; Morganti AG; Cammelli S
Anticancer Res; 2020 Jan; 40(1):465-472. PubMed ID: 31892602
[TBL] [Abstract][Full Text] [Related]
5. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study).
Comito T; Massaro M; Teriaca MA; Franzese C; Franceschini D; Navarria P; Clerici E; Di Cristina L; Bertolini A; Tomatis S; Reggiori G; Bresolin A; Bozzarelli S; Rimassa L; Bonifacio C; Carrara S; Santoro A; Zerbi A; Scorsetti M
Curr Oncol; 2023 Jul; 30(7):7073-7088. PubMed ID: 37504373
[TBL] [Abstract][Full Text] [Related]
6. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy.
Zhang A; Ren S; Yuan Y; Li X; Zhu X; Jiang L; Li D; Zuo C
Medicine (Baltimore); 2019 Mar; 98(13):e15064. PubMed ID: 30921238
[TBL] [Abstract][Full Text] [Related]
11. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.
Wild AT; Hiniker SM; Chang DT; Tran PT; Khashab MA; Limaye MR; Laheru DA; Le DT; Kumar R; Pai JS; Hargens B; Sharabi AB; Shin EJ; Zheng L; Pawlik TM; Wolfgang CL; Koong AC; Herman JM
J Gastrointest Oncol; 2013 Dec; 4(4):343-51. PubMed ID: 24294505
[TBL] [Abstract][Full Text] [Related]
12. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
Jiang W; Haque W; Verma V; Butler EB; Teh BS
Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
[No Abstract] [Full Text] [Related]
14. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.
Ma SJ; Prezzano KM; Hermann GM; Singh AK
Radiat Oncol; 2018 Nov; 13(1):214. PubMed ID: 30400962
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
